These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11668222)

  • 21. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects.
    Rahmani M; Raiszadeh F; Allahverdian S; Kiaii S; Navab M; Azizi F
    Atherosclerosis; 2002 Jun; 162(2):381-9. PubMed ID: 11996958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.
    Saku K; Zhang B; Hirata K; Okura Y; Bai H; Liu R; Arakawa K
    Eur J Clin Pharmacol; 1993; 44(6):535-9. PubMed ID: 8405008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid peroxidation is increased in paraoxonase L55 homozygotes compared with M-allele carriers.
    Malin R; Laine S; Rantalaiho V; Wirta O; Pasternack A; Jokela H; Alho H; Koivula T; Lehtimäki T
    Free Radic Res; 2001 May; 34(5):477-84. PubMed ID: 11378531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum paraoxonase activity decreases in rheumatoid arthritis.
    Tanimoto N; Kumon Y; Suehiro T; Ohkubo S; Ikeda Y; Nishiya K; Hashimoto K
    Life Sci; 2003 May; 72(25):2877-85. PubMed ID: 12697270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coronary plaque regression and lifestyle modification in patients treated with pravastatin. - Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol -.
    Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Matsumoto M; Washio T; Kumabe N; Hirayama A
    Circ J; 2010 May; 74(5):954-61. PubMed ID: 20234098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS).
    Streja L; Packard CJ; Shepherd J; Cobbe S; Ford I;
    Am J Cardiol; 2002 Oct; 90(7):731-6. PubMed ID: 12356386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers.
    Sierksma A; van der Gaag MS; van Tol A; James RW; Hendriks HF
    Alcohol Clin Exp Res; 2002 Sep; 26(9):1430-5. PubMed ID: 12351939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet.
    Schulpis KH; Bartzeliotou A; Tsakiris S; Gounaris A; Papassotiriou I
    Eur J Clin Nutr; 2007 Jun; 61(6):803-8. PubMed ID: 17203019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
    Himbergen TM; van Tits LJ; Voorbij HA; de Graaf J; Stalenhoef AF; Roest M
    J Intern Med; 2005 Nov; 258(5):442-9. PubMed ID: 16238680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PON1 M/L55 mutation protects high-risk patients against coronary artery disease.
    Oliveira SA; Mansur AP; Ribeiro CC; Ramires JA; Annichino-Bizzacchi JM
    Int J Cardiol; 2004 Mar; 94(1):73-7. PubMed ID: 14996478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pravastatin effects on lipoproteins, Lp (a), apo B and apo A-1 in patients with primary hypercholesterolemia].
    Novazzi JP; Fonseca FA; Feres MC; da Silva RC; Lima JC; Martinez TL
    Arq Bras Cardiol; 1994 Jun; 62(6):395-8. PubMed ID: 7826229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.
    Cobbaert C; Jukema JW; Zwinderman AH; Withagen AJ; Lindemans J; Bruschke AV
    J Am Coll Cardiol; 1997 Nov; 30(6):1491-9. PubMed ID: 9362407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotypes of Common Polymorphisms in the PON1 Gene Associated with Paraoxonase Activity as Cardiovascular Risk Factor.
    Moreno-Godínez ME; Galarce-Sosa C; Cahua-Pablo JÁ; Rojas-García AE; Huerta-Beristain G; Alarcón-Romero LDC; Cruz M; Valladares-Salgado A; Antonio-Véjar V; Ramírez-Vargas MA; Flores-Alfaro E
    Arch Med Res; 2018 Oct; 49(7):486-496. PubMed ID: 30853125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults.
    Janatuinen T; Laaksonen R; Vesalainen R; Raitakari O; Lehtimäki T; Nuutila P; Knuuti J
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):561-8. PubMed ID: 11588526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study.
    Kunnas TA; Lehtimäki T; Laaksonen R; Ilveskoski E; Janatuinen T; Vesalainen R; Nuutila P; Karhunen PJ; Knuuti J; Nikkari ST
    J Mol Med (Berl); 2002 Dec; 80(12):802-7. PubMed ID: 12483466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein A-I gene polymorphisms: frequency in patients with coronary artery disease and healthy controls and association with serum apo A-I and HDL-cholesterol concentration.
    Wile DB; Barbir M; Gallagher J; Myant NB; Ritchie CD; Thompson GR; Humphries SE
    Atherosclerosis; 1989 Jul; 78(1):9-18. PubMed ID: 2569310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
    Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
    Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A
    Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.